Mode
Text Size
Log in / Sign up

Cocaine use disorder prevalence in bipolar disorder is 10.94 percent with worse clinical outcomesOne in ten people with bipolar disorder also struggles with cocaine use

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that bipolar disorder with cocaine use disorder is associated with worse clinical outcomes and requires integrated treatment approaches.

This is a systematic review, meta-analysis, and meta-regression on the prevalence and clinical correlates of cocaine use disorder (CUD) in individuals with bipolar disorder (BD). The analysis pooled data from 6,150,881 individuals with BD. The primary finding is a pooled overall prevalence of CUD in BD of 10.94 percent (95% CI: 6.15-18.73). In studies that included primary substance use disorder samples, the prevalence was 46.25 percent (95% CI: 34.77-58.15). The authors synthesize that BD individuals with comorbid CUD, compared to those without CUD, have worse affective symptoms, higher rates of psychiatric comorbidities (e.g., post-traumatic stress disorder, attention-deficit/hyperactivity disorder), more polysubstance use, and lower medication adherence. Cognitive performance, specifically delayed recall, was slightly better in BD+CUD patients versus those with BD and alcohol use disorder. A key limitation noted by the authors is high heterogeneity across studies. The authors highlight the need for integrated treatment strategies and greater clinical attention to this comorbidity, but the evidence is observational and does not establish causality.

One in ten people with bipolar disorder also struggles with cocaine use disorder. This is a serious problem because it makes the illness much harder to manage. A new analysis looked at data from over 6,000 individuals to understand how common this combination is. The results show that nearly 11 percent of people with bipolar disorder also have cocaine use disorder. That number rises to 46 percent when researchers looked only at studies focused on people with substance use disorders.

People with both conditions face tougher challenges. They often have worse mood symptoms and higher rates of other mental health issues like post-traumatic stress disorder or attention-deficit/hyperactivity disorder. They are more likely to use multiple substances at once and struggle to stick to their medication plans. These factors make their overall health and daily life more difficult.

The study also looked at how thinking skills change. Patients with both bipolar disorder and cocaine use disorder actually performed slightly better on memory tests than those with bipolar disorder and alcohol use disorder. However, the researchers noted that the studies they reviewed were very different from one another. This mix of study types makes it hard to draw one single conclusion about the exact risks involved.

What this means for you:
About 11% of people with bipolar disorder also have cocaine use disorder, requiring integrated care.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
INTRODUCTION: Substance Use Disorders (SUD) are among the most common comorbidities in individuals with Bipolar Disorder (BD). However, the prevalence of cocaine use disorder (CUD) and its impact on the clinical course of BD have not been extensively explored and synthesized to date. OBJECTIVE: To estimate the prevalence of CUD among individuals with BD and describe its associated clinical correlates. METHODS: We conducted a systematic review with meta-analysis and meta-regression following PRISMA guidelines. Six databases were searched through December 2024. We included observational studies reporting CUD prevalence or clinical comparisons between BD individuals with and without CUD. Risk of bias was assessed using the Newcastle-Ottawa Scale. A random-effects model was used for meta-analyses. RESULTS: Twenty-seven studies comprising 6150,881 individuals with BD were included in the meta-analysis. The pooled overall prevalence of CUD in BD was 10.94% (95% CI: 6.15-18.73), rising to 46.25% (95% CI: 34.77-58.15) in studies including primary SUD samples; heterogeneity across studies was high. Seven studies were included in the qualitative synthesis of clinical correlates. BD+CUD individuals showed worse affective symptoms, higher rates of psychiatric comorbidities (e.g., post-traumatic stress disorder, attention-deficit/hyperactivity disorder), polysubstance use, and lower medication adherence compared to BD individuals without comorbid CUD. Sociodemographic vulnerability and increased risk behaviors were also more frequent. Although cognitive performance was broadly similar, BD+CUD patients performed slightly better than BD+AUD in delayed recall, possibly reflecting substance-specific effects. CONCLUSION: CUD is common among individuals with BD and is associated with more severe clinical profiles. Findings highlight the need for integrated treatment strategies and greater clinical attention to this comorbidity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.